
Claims

1. Use of an IL-8 inhibitor in the manufacture of a medicament for the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB), wherein said IL-8 inhibitor is a CXCR1 inhibitor or a dual CXCR1 and CXCR2 inhibitor.

2. The use of claim 1, wherein said IC/PBS and/or over active bladder (OAB) is induced by anticancer therapy or radiotherapy to the pelvis.

3. The use of claim 1 or claim 2, wherein said IL-8 inhibitor is a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof,

wherein

R1 is hydrogen;

X is OH;


R2 is hydrogen or linear C_1-C_4 alkyl;

Y is a heteroatom selected from S, O and N;

Z is selected from linear or branched C_1-C_4 alkyl, linear or branched C_1-C_4 alkoxy, halo C_1-C_3 alkyl and halo C_1-C_3 alkoxy.

4. The use of any one of claims 1 to 3, wherein said IL-8 inhibitor is selected from (R,S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)propanoic acid and (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino} phenyl) propanoic acid, preferably as sodium salt.

5. The use of claim 1 or claim 2, wherein said IL-8 inhibitor is a compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof,

wherein

R' is hydrogen;

R is a residue of formula SO_2Ra wherein Ra is linear or branched C_1-C_4 alkyl or halo C_1-C_3 alkyl.


6. The use of any one of claims 1 to 2 and 5, wherein said IL-8 inhibitor is R(-)-2-[(4'-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide, preferably the sodium salt thereof.

7. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB) wherein the pharmaceutical composition comprises an IL-8 inhibitor wherein the IL-8 inhibitor is:

a) a CXCR1 inhibitor or a dual CXCR1 and CXCR2 inhibitor;

b) selected from a small molecule, antibody or peptide;

c) a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof,

wherein

R1 is hydrogen;


X is OH;

R2 is hydrogen or linear C_1-C_4 alkyl;

Y is a heteroatom selected from S, O and N;

Z is selected from linear or branched C_1-C_4 alkyl, linear or branched C_1-C_4 alkoxy, halo C_1-C_3 alkyl and halo C_1-C_3 alkoxy; or

d) a compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof,

wherein

R' is hydrogen;

R is a residue of formula SO_2Ra wherein Ra is linear or branched C_1-C_4 alkyl or halo C_1-C_3 alkyl.

8. The use as claimed in claim 7, wherein said IL-8 inhibitor is selected from (R,S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)propanoic acid and (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino} phenyl) propanoic acid, preferably as sodium salt, or wherein said IL-8 inhibitor is R(-)-2-[(4'-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide, preferably the sodium salt thereof.

9. The use as claimed in claim 7 or claim 8, wherein the pharmaceutical composition further comprises one further pharmaceutically active compound.


10. Use of a product or kit comprising:

A) a medicament for the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB) comprising an IL-8 inhibitor wherein the IL-8 inhibitor is:

a) a CXCR1 inhibitor or a dual CXCR1 and CXCR2 inhibitor;

b) selected from a small molecule, antibody or peptide;

c) a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof,

wherein

R1 is hydrogen;


X is OH;

R2 is hydrogen or linear C_1-C_4 alkyl;

Y is a heteroatom selected from S, O and N;

Z is selected from linear or branched C_1-C_4 alkyl, linear or branched C_1-C_4 alkoxy, halo C_1-C_3 alkyl and halo C_1-C_3 alkoxy; or

d) a compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof,

wherein

R' is hydrogen;

R is a residue of formula SO_2Ra wherein Ra is linear or branched C_1-C_4 alkyl or halo C_1-C_3 alkyl,

or the medicament according to claim 7 or claim 8, and

B) at least one further pharmaceutically active compound

A) and B) being two separate formulations for simultaneous, separate or sequential use,

wherein said IL-8 inhibitor is selected from (R,S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)pro-panoic acid and (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl) pro-panoic acid, preferably as sodium salt, or wherein said IL-8 inhibitor is R(-)-2-[(4'-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide, preferably the sodium salt thereof in the manufacture of a medicament for the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB).

11. The use as claimed in claim 9 or claim 10, wherein said further pharmaceutically active compound is an active compound useful for the prevention and treatment of IC/PBS, and/or OAB.

12. The use as claimed in claim 11, wherein said further pharmaceutically active compound is a TRPV1 antagonist.

13. The use as claimed in claim 9 or claim 10, wherein said further pharmaceutically active compound is a drug that induces, as an undesired effect, IC /PBS or OAB.

14. The use as claimed in claim 13, wherein said further pharmaceutically active compound is selected from cyclophosphamide, Bacillus Calmette-Guérin to be instilled directly into the bladder, mitomycin C, Adriamycin or tiaprofenic acid.